“The operation of an insulin pump using a consumer electronic device, such as a smart phone, is a top area of interest in our next generation pump development efforts,“ said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “As the only company with experience in the use of touchscreen insulin pump control, we are uniquely positioned to identify new ways to safely utilize the computing power of our everyday consumer devices to operate a life-sustaining infusion pump. This patent reflects our foresight to integrate consumer and medical device technologies to further our mission to simplify the lives of people with diabetes and covers key features we believe will be beneficial for commercial adoption in the future.”
Tandem Diabetes' latest patent (No. 9,737,656) is titled, “Integration of Infusion Pump with Remote Electronic Device,” and expires in 2035. The company has a related U.S. continuation application on file, as well as a pending application in Europe.
This newly issued patent raises Tandem Diabetes Care’s patent portfolio to 56 issued U.S. patents and 50 pending U.S. patent applications. In addition, the company has, and is seeking, patent protection for proprietary technologies in other countries throughout the world.
Tandem Diabetes Care manufactures the only touchscreen insulin pumps available in the United States. The company takes a user-centric and integrated approach to the design, development and commercialization of products for diabetics who use insulin. The company manufactures and sells the t:slim X2 Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, the t:flex Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4 Insulin Pump, the first continuous glucose monitoring-enabled pump with touch-screen simplicity. Tandem is based in San Diego, Calif. Tandem Diabetes Care, t:connect and t:flex are registered trademarks, and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care Inc.